InvestorsHub Logo
Followers 18
Posts 3031
Boards Moderated 0
Alias Born 01/28/2017

Re: None

Monday, 03/16/2020 11:55:14 AM

Monday, March 16, 2020 11:55:14 AM

Post# of 1166
"HAUPPAUGE, N.Y., March 12, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that it has entered into a worldwide strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus and IgM and IgG antibodies on both the LumiraDx and Chembio DPP platforms.

“We are pleased to expand our relationship with Chembio as our partner given the company’s expertise and speed in developing high-quality point-of-care assays. By joining forces and bringing together the best of these two companies, we believe we will become the chosen approach for the detection and monitoring of the COVID-19 virus, which has become a worldwide pandemic,” stated Ron Zwanziger, LumiraDx's Chairman and Chief Executive Officer."

Expecting Huge Follow-up News!!